News

Press Releases

June 4, 2022
CG Oncology Presents New Clinical Data on Two Ongoing Programs at The American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

May 16, 2022
CG Oncology Presents Additional Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

April 13, 2022
CG Oncology Presents Interim Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

December 20, 2021
CG Oncology Announces First Patient Dosed in Japan in Phase 3 Monotherapy Study of CG0070 in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

November 13, 2021
CG Oncology Presents Preliminary Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

September 22, 2021
CG Oncology and Roche to Collaborate on Clinical Trial of Oncolytic Immunotherapy CG0070 as Part of Novel Combination for Various Solid Tumor Indications

September 9, 2021
CG Oncology Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Oncolytic Immunotherapy CG0070 in Combination with OPDIVO® (nivolumab) in Metastatic Urothelial Cancer

December 10, 2020
CG Oncology Closes $47 Million Series D Financing

December 9, 2020
CG Oncology Announces First Patient Dosed in Phase 2 Clinical Trial of CG0070, an Oncolytic Immunotherapy, in Combination with KEYTRUDA® (pembrolizumab) for Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

November 12, 2020
CG Oncology Announces First Patient Dosed in Phase 1b Study of Oncolytic Immunotherapy CG0070 in Combination with OPDIVO® (nivolumab) in Muscle-Invasive Bladder Cancer

March 26, 2020
CG Oncology Announces License and Commercialization Agreement with Kissei Pharmaceutical Co., Ltd. for CG0070 in Japan and Other Asian Countries

March 25, 2020
Cold Genesys Announces Name Change to CG Oncology

March 18, 2019
Cold Genesys Closes $22 Million Series C Financing

November 28, 2018
Cold Genesys Announces Clinical Trial Collaboration to Evaluate the Combination of CG0070 and KEYTRUDA^® (pembrolizumab) in Bladder Cancer

October 22, 2018
Cold Genesys Announces New Leadership Appointments

May 15, 2017
Cold Genesys Announces Clinical Results at American Urological Association (AUA) Annual Meeting 2017

April 25, 2017
Cold Genesys Announces Acceptance of Late Breaking Abstract at American Urological Association (AUA) Annual Meeting 2017​

October 19, 2015
Cold Genesys Announces FDA Acceptance of a Phase I/II Clinical Trial Using CG0070 Plus an Anti-CTLA-4 Checkpoint Inhibitor as a Neo-Adjuvant Immunotherapy for Muscle Invasive Bladder Cancer​

August 5, 2015
Cold Genesys Secures Series B Investment for Pivotal and Combo Immunotherapy Trials - Ally Bridge and WI Harper Co-lead US$10 million Series B Financing

July 30, 2014
Cold Genesys Raises $13.57 Million in a Series A Round of Financing to Accelerate Its Ongoing Phase II/III Clinical Trial for Bladder Cancer

Conferences & Media

October 12, 2021
CG Oncology to Present Two Programs at The Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

December 8, 2020
Biocom California Announces Fifth Annual Life Science Catalyst Award Winners

December 3, 2020
Presenting at Society of Urologic Oncology (SUO) Meeting
Virtual - December 3-5, 2020

October 6, 2020
Presenting at CHI's Immuno-Oncology Summit
Virtual - October 6-8, 2019

December 3, 2019
Cold Genesys CEO Arthur Kuan Named to 2020 Forbes' 30 Under 30

November 7, 2019
Presenting at Asia Pacific Consortium of Gene and Cell Therapy (APCGCT)
Seoul, South Korea - November 7-8, 2019

October 9, 2019
Presenting at International Oncolytic Virus Conference (IOVC)
Rochester, MN - October 9-12, 2019

August 5, 2019
Presenting at CHI's Immuno-Oncology Summit
Boston, MA - August 5-9, 2019

April 29, 2019
Presenting at American Society of Gene & Cell Therapy (ASGCT) Meeting
Washington, D.C. - April 29-May 2, 2019

April 11, 2019
Presenting at Essential Protein Engineering & Cell Therapy Summit (PEGS)
Boston, MA - April 11-12, 2019

November 28, 2018
Presenting at Society of Urologic Oncology (SUO) Meeting
Phoenix, AZ - November 28-30, 2018

June 1, 2018
Presenting at American Society of Clinical Oncology (ASCO) Meeting
Chicago, IL - June 1-5, 2018

May 18, 2018
Presenting at American Urological Association (AUA) Meeting
San Francisco, CA - May 18-21, 2018

February 29, 2016
BioCentury, Infectious Enthusiasm (pdf)

September 9, 2015
2015 BIO Investor Forum Buzz of BIO Winners Announced - Recognizing Highly Innovative Companies in the Biotech Sector